Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas. Kocakavuk E, Johnson KC, Sabedot TS, Reinhardt HC, et al. Neuro Oncol 2023 Jun 17:noad095. doi: 10.1093.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kocakavuk E, Johnson KC, Sabedot TS, Reinhardt HC, et al. Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas. Neuro Oncol 2023 Jun 17:noad095. doi: 10.1093.
PMID: 37329568